COST-EFFECTIVENESS ANALYSIS OF STRATEGIES OF AUTOLOGOUS STEM-CELL TRANSPLANTATION AND MAINTENANCE THERAPY FOR TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA IN CHINA

被引：0
|
作者：
Wu, W. [1 ]
Lou, Y. [1 ]
Fan, X. [1 ]
Ding, S. [1 ]
Zhou, Y. [1 ]
Keramat, S. A. [2 ]
Yang, W. [1 ]
Tang, F. [1 ]
Comans, T. [2 ]
Dong, H. [1 ]
机构：
[1] Zhejiang Univ, Hangzhou, Peoples R China
[2] Univ Queensland, Brisbane, Qld, Australia
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE732
引用
收藏
页码：S195 / S195
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF EARLY VERSUS DELAYED AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR MULTIPLE MYELOMA (MM)
    Kelkar, Amar
    Midha, Shonali
    Richardson, Paul
    Anderson, Kenneth
    Munshi, Nikhil
    Laubach, Jacob
    Ghobrial, Irene
    Mo, Clifton
    Nadeem, Omar
    Cliff, Edward
    Abel, Gregory
    Soiffer, Robert
    Cutler, Corey
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 107 - 108
  • [22] Long Term Evaluation of the Impact of Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: A Cost-Effectiveness Analysis
    Corso, Alessandro
    Mangiacavalli, Silvia
    Cocito, Federica
    Pascutto, Cristiana
    Ferretti, Virginia Valeria
    Pompa, Alessandra
    Ciampichini, Roberta
    Pochintesta, Lara
    Mantovani, Lorenzo G.
    PLOS ONE, 2013, 8 (09):
  • [23] Frontline treatment in multiple myeloma patients not eligible for stem-cell transplantation
    Facon, Thierry
    Darre, Stephane
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2007, 20 (04) : 737 - 746
  • [24] Cost-Effectiveness Analysis of Lenalidomide for Maintenance Therapy after Autologous Stem Cell Transplant (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM) Patients: A United States Payer Perspective
    Zhou, Zheng-Yi
    Parikh, Kejal
    Chai, Xinglei
    Rokito, Ariel
    Udeze, Chuka
    Xie, Jipan
    Agarwal, Amit
    BLOOD, 2018, 132
  • [25] Role of new drugs incorporated into consolidation and maintenance therapy in transplant-eligible multiple myeloma patients
    Gentile, Massimo
    Vigna, Ernesto
    Recchia, Anna G.
    Morabito, Lucio
    Martino, Massimo
    Morabito, Fortunato
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (10) : 1315 - 1320
  • [26] COST-EFFECTIVENESS OF INDUCTION TREATMENT WITH BORTEZOMIB ADDED TO THALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN GERMANY
    van Beurden-Tan, C.
    Rosinol, L.
    Diels, J.
    Wirth, D.
    Chirita, O.
    Lahuerta, J. J.
    Gaugris, S.
    Marsh, S.
    San Miguel, J.
    Spencer, M.
    Treur, M.
    Blade, J.
    VALUE IN HEALTH, 2013, 16 (07) : A409 - A410
  • [27] The role of autologous stem-cell transplantation in multiple myeloma in 2021
    Mina, Roberto
    Gay, Francesca
    CURRENT OPINION IN ONCOLOGY, 2021, 33 (06) : 642 - 647
  • [28] Autologous Stem-Cell Transplantation for Multiple Myeloma AUTHORS REPLY
    Harousseau, Jean-Luc
    Moreau, Philippe
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (11): : 1119 - 1119
  • [29] Allogeneic stem-cell transplantation for early relapse of multiple myeloma after autologous stem-cell transplantation
    Schmidt, V
    Mugge, L-O
    Klink, A.
    Hilgendorf, I
    Hochhaus, A.
    Sayer, H. G.
    Oncology Research and Treatment, 2015, 38 : 128 - 129
  • [30] No Role for Tandem Autologous Stem Cell Transplantation in Modern Treatment Paradigms for Transplant Eligible Multiple Myeloma
    Baljevic, Muhamed
    Biltibo, Eden Ayele
    Dholaria, Bhagirathbhai
    Sengsayadeth, Salyka
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (09): : 829 - 831
12345